Session » SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1813

A Comprehensive Method to Study Environmental Chemicals in Serum in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1797

A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years

9:00AM-11:00AM: Abstract Number: 1796

A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment

9:00AM-11:00AM: Abstract Number: 1803

Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients

9:00AM-11:00AM: Abstract Number: 1819

Altered Brain Functional Connectivity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1801

An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation

9:00AM-11:00AM: Abstract Number: 1788

Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1800

Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California

9:00AM-11:00AM: Abstract Number: 1790

Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1817

Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1810

Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 1787

Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients

9:00AM-11:00AM: Abstract Number: 1811

Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity

9:00AM-11:00AM: Abstract Number: 1815

Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1821

Early Assessment of Left Ventricular Assessment Using Speckle Tracking Echocardiography and It´s Relationship with Insulin Resistance in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1808

Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1799

High Fat-Diet as a Catalyst to Lupus Development and Autoimmunity in MRL/lpr Mice

9:00AM-11:00AM: Abstract Number: 1798

IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up

9:00AM-11:00AM: Abstract Number: 1818

IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1804

Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1795

Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1805

Longitudinal Analysis of IFN Status and Disease Characteristics in SLE

9:00AM-11:00AM: Abstract Number: 1812

Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients

9:00AM-11:00AM: Abstract Number: 1792

Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE

9:00AM-11:00AM: Abstract Number: 1791

Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1793

Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

9:00AM-11:00AM: Abstract Number: 1809

Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters

9:00AM-11:00AM: Abstract Number: 1820

Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity

9:00AM-11:00AM: Abstract Number: 1794

Systemic Lupus Erythematosus and Geomagnetic Disturbances: A Time Series Analysis

9:00AM-11:00AM: Abstract Number: 1806

The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1814

The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1807

The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1789

Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels

9:00AM-11:00AM: Abstract Number: 1816

Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1802

Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].